MedTrace Logo

Study of XH-S003 in Healthy Volunteers

NCT06272747 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2025-05-21

No results posted yet for this study

Summary

The purpose of the study is to assess the safety, tolerability and pharmacokinetics of XH-S003 in healthy volunteers under SAD (Single ascending dose) and MAD (Multiple ascending dose) studies. In addition, this study evaluates the food effects of XH-S003.

Conditions

  • Healthy Adults

Interventions

DRUG

XH-S003

IP: XH-S003 Dose: 25 mg, 100 mg Dose Formulation: Capsule Route of Administration: Oral

DRUG

Placebo

Dose: 25 mg, 100 mg Dose Formulation: Capsule Route of Administration: Oral

Sponsors & Collaborators

  • S-INFINITY Pharmaceuticals Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-07-10
Primary Completion
2024-07-30
Completion
2024-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06272747 on ClinicalTrials.gov